Evolving DLBCL Treatment Landscape: Interpreting ASH 5-Year Polatuzumab Data in Clinical Practice : Episode 1
Advances in DLBCL Management: Long-Term Treatment Outcomes
Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting its meaningful progression-free survival (PFS) and overall survival (OS) results for first-line patients with DLBCL and emphasizing key long-term safety considerations for clinicians.
Video Player is loading.
Video content above is prompted by the following:
- Please provide an overview of the 5-year efficacy and safety outcomes from the recent ASH data on polatuzumab in DLBCL.
- What do these data mean for patients with first-line DLBCL and why are the PFS and OS results clinically meaningful?
- What are the most significant long-term safety considerations that clinicians should know?
Recent Videos
Clinical Case – A Patient With Steroid-Refractory cGVHD
Long-Term Outcomes and Treatment Guidelines in DLBCL Management
Academic Perspectives on the Evolving Treatment Landscape in MPNs
Lenvatinib in Advanced HCC: Considerations for Monotherapy and Combination Regimens
First-Line Therapy for Advanced HCC: The Role of TKIs and ICIs
Case 3—HER2-Mutated Metastatic NSCLC: Presentation and Discussion
Case 2 (cont.)—Metastatic NSCLC With a ROS1 Alteration: Patients With CNS Disease
Adverse Events Monitoring and Management in BPDCN Treatment
Academic Perspectives on Treatment Decisions for BPDCN
Next-Generation Approaches and Future Directions in PV Care
Related Content
